
    
      This six month double-blind,randomized trial is designed to compare the efficacy of high dose
      long acting risperidone ( 75 mg-100 mg q2 weeks or its equivalent) with standard doses of
      long acting risperidone (â‰¤50 mg/q 2weeks) for Total Psychopathology, positive, negative, and
      depressive symptoms, and cognition in patients who are considered to be poor responders by
      themselves, significant others, or clinicians. This will include two types of inadequately
      responding patients-those who are treatment resistant by research criteria (Kane et al.,
      1988) and those with inadequate response
    
  